CD8-positive, alpha-beta T cell (CD8+ αβ T cell)

"CD8-positive, alpha-beta T cell activation" refers not to a single molecular target, but to the functional process by which **CD8+ αβ T cells**—a subset of cytotoxic T lymphocytes expressing the CD8 coreceptor and a heterodimeric alpha-beta T cell receptor (TCR)—become activated. Activation occurs when these immune cells recognize peptide antigens presented by major histocompatibility complex class I (MHC I) molecules on antigen-presenting cells, in combination with costimulatory signals and cytokine cues[3][5][1]. This process results in clonal expansion, acquisition of effector functions such as perforin- and granzyme-mediated cytotoxicity, production of cytokines, and the elimination of infected, malignant, or otherwise abnormal cells[3][5][4]. The term as presented—"CD8-positive, alpha-beta T cell activation"—describes a **cellular event**, not a molecular entity or canonical drug target. Although elements of the activation process (such as the **CD8 coreceptor**, **T-cell receptor alpha-beta**, **co-stimulatory molecules** like CD28, or intracellular signaling kinases) are legitimate molecular targets in drug development, "CD8-positive, alpha-beta T cell activation" as a phrase is too broad to map to a single canonical molecule, receptor, or enzyme[1][3][5]. **Correction/clarification:** - The provided name is incorrect as a therapeutic target; it refers to an **immune process involving CD8+ αβ T cells**, not a discrete druggable protein, receptor, or molecule. - Individual molecular targets relevant to this process include the **CD8 coreceptor** (CD8α and CD8β chains), the **T-cell receptor alpha-beta complex (TCRαβ)**, the **major histocompatibility complex class I (MHC I)** molecules, and key downstream signaling molecules. - Drug development efforts typically focus on individual components (e.g., CD8, TCR, immune checkpoints like PD-1). **Summary:** "CD8-positive, alpha-beta T cell activation" describes a fundamental immunological process essential for adaptive cytotoxic immune responses, but is not itself a canonical molecular target. For structured databases, it should be remapped to specific molecules—such as "CD8 coreceptor" or "T-cell receptor alpha-beta"—when relevant[1][3][5].

Other names

CD8+ T cellCD8-positive T lymphocytecytotoxic T lymphocyte (CTL)CD8 T cellcytotoxic T cell

Not applicable (see above—immunotherapies can harness, suppress, or redirect CD8+ T cells; for example, immune checkpoint blockade releases inhibition on these cells, but does not directly modulate a single receptor called "CD8-positive, alpha-beta T cell activation")